Cite
HARVARD Citation
Chari, A. et al. (2020). Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma. Hematological oncology. 38 (3), pp. 353-362. [Online].